Golden State Wealth Management LLC Buys 113 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Golden State Wealth Management LLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3,766.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116 shares of the company’s stock after purchasing an additional 113 shares during the period. Golden State Wealth Management LLC’s holdings in IDEXX Laboratories were worth $49,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of IDXX. Hurley Capital LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Colonial Trust Co SC lifted its position in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after buying an additional 39 shares during the last quarter. Itau Unibanco Holding S.A. boosted its stake in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock worth $40,000 after acquiring an additional 81 shares during the period. Finally, Retirement Wealth Solutions LLC increased its holdings in shares of IDEXX Laboratories by 40.0% during the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company’s stock worth $44,000 after acquiring an additional 30 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $542.65 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $546.39. The company’s 50 day moving average price is $504.03 and its two-hundred day moving average price is $452.31. The firm has a market cap of $43.64 billion, a PE ratio of 50.15, a PEG ratio of 3.92 and a beta of 1.54. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. During the same period in the previous year, the company posted $2.71 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the firm’s stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IDXX. Stifel Nicolaus raised their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a report on Monday, May 19th. Leerink Partners raised their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 11th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Finally, Jefferies Financial Group started coverage on IDEXX Laboratories in a report on Tuesday. They set a “buy” rating and a $625.00 price objective for the company. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $554.78.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.